低分子肝素治疗重症急性胰腺炎的治疗现状及进展
Current Status and Progress of Low Molecular Weight Heparin in the Treatment of Severe Acute Pancreatitis
摘要: 重症急性胰腺炎(SAP)是常见的消化系统危重疾病，有发病急、进展快、死亡率高等特点。低分子肝素(Low molecular weight heparins, LMWH)是一种常见的抗凝血酶制剂，同时在抗炎方面具有显著的作用，能抑制胰酶的产生、加速胰腺再生并改善胰腺微循环，从而提高SAP的生存率。但近几年有研究表明低分子肝素并不能显著降低SAP的手术率和死亡率。低分子肝素是否有利于急性重症胰腺炎的预后仍存在争议。本文就低分子肝素治疗SAP的治疗现状及进展做一综述，为临床上治疗SAP提供参考。
Abstract: Severe acute pancreatitis (SAP) is a common critical disease of digestive system, which has the characteristics of acute onset, rapid progress and high mortality. Low molecular weight heparin (LMWH) is a common antithrombin preparation. At the same time, it plays a significant role in anti-inflammatory. It can inhibit the production of pancreatic enzyme, accelerate pancreatic regeneration and improve pancreatic microcirculation, so as to improve the survival rate of SAP. However, in recent years, studies have shown that low molecular weight heparin can not significantly reduce the operation rate and mortality of SAP. Whether low molecular weight heparin is beneficial to the prognosis of severe acute pancreatitis is still controversial. This paper reviews the current situation and progress of low molecular weight heparin in the treatment of sap, so as to provide reference for the clinical treatment of SAP.
文章引用：黄东, 杨慷. 低分子肝素治疗重症急性胰腺炎的治疗现状及进展[J]. 临床医学进展, 2021, 11(11): 5095-5100. https://doi.org/10.12677/ACM.2021.1111751

参考文献

[1] 魏艳丽. 重症急性胰腺炎的治疗现状[J]. 医学信息, 2021, 34(19): 55-57.
[2] Hines, O.J. and Pandol, S.J. (2019) Management of Severe Acute Pancreatitis. BMJ, 367, l6227. [Google Scholar] [CrossRef] [PubMed]
[3] 韩雪, 陈治国, 郝欣. 低分子肝素治疗重症急性胰腺炎疗效的META分析[J]. 中华医院感染学杂志, 2021, 31(1): 99-104.
[4] Hao, C., Sun, M., Wang, H., et al. (2019) Low Molecular Weight Heparins and Their Clinical Applications. Progress in Molecular Biology and Translational Science, 163, 21-39. [Google Scholar] [CrossRef] [PubMed]
[5] Tozlu, M., Kayar, Y., Ince, A.T., et al. (2019) Low Molecular Weight Heparin Treatment of Acute Moderate and Severe Pancreatitis: A Randomized, Controlled, Open-Label Study. The Turkish Journal of Gastroenterology: The Official Journal of Turkish Society of Gastroenterology, 30, 81-87.
[6] Sarr, M.G. (2013) 2012 Revision of the Atlanta Classification of Acute Pancreatitis. Polskie Archiwum Medycyny Wewnetrznej, 123, 118-124. [Google Scholar] [CrossRef] [PubMed]
[7] 杜奕奇, 陈其奎, 李宏宇, 等. 中国急性胰腺炎诊治指南(2019年, 沈阳) [J]. 临床肝胆病杂志, 2019, 35(12): 2706-2711.
[8] 郑智, 曲元旭, 丁乙轩, 等. 急性胰腺炎发病机制的研究进展[J]. 中华肝胆外科杂志, 2021, 27(2): 152-155.
[9] Watanabe, T., Kudo, M. and Strober, W. (2017) Immunopathogenesis of Pancreatitis. Mucosal Immunology, 10, 283-298. [Google Scholar] [CrossRef] [PubMed]
[10] Lu, X.S., et al. (2009) Low Molecular Weight Heparin in the Treatment of Severe Acute Pancreatitis: A Multiple Centre Prospective Clinical Study. Asian Journal of Surgery, 32, 89-94. [Google Scholar] [CrossRef] 
[11] 陈茹茹, 罗厚江, 杨军. 低分子量肝素作用机制及临床应用研究进展[J]. 中国现代医生, 2021, 59(6): 182-186.
[12] Li, S., Zhang, S., Li, R., et al. (2020) Prophylactic Low-Molecular-Weight Heparin Administration Protected against Severe Acute Pancreatitis Partially by VEGF/Flt-1 Signaling in a Rat Model. Human & Experimental Toxicology, 39, 1345-1354. [Google Scholar] [CrossRef] [PubMed]
[13] 魏巍. 低分子肝素治疗重症急性胰腺炎的效果研究[J]. 中国现代药物应用, 2021, 15(4): 201-203.
[14] Lu, X.-S., et al. (2010) Effect of Lower-Molecular Weight Heparin in the Prevention of Pancreatic Encephalopathy in the Patient with Severe Acute Pancreatitis. Journal of the Pancreas, 39, 516. [Google Scholar] [CrossRef] 
[15] 郭致平, 窦杰, 吴雪松, 等. 抗凝药物治疗重症急性胰腺炎的临床效果观察[J]. 昆明医科大学学报, 2017, 38(3): 35-38.
[16] Qiu, Q., Li, G.J., Tang, L., et al. (2019) The Efficacy of Low Molecular Weight Heparin in Severe Acute Pancreatitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Digestive Diseases, 20, 512-522. [Google Scholar] [CrossRef] [PubMed]
[17] Ke, L., et al. (2014) Efficacy of Continuous Regional Arterial Infusion with Low-Molecular-Weight Heparin for Severe Acute Pancreatitis in a Porcine Model. Shock (Augusta, Ga.), 41, 443-448. [Google Scholar] [CrossRef] 
[18] 艾敏, 刘丽, 卢光明, 等. 低分子肝素钙持续性区域动脉灌注治疗重症急性胰腺炎8例[J]. 介入放射学杂志, 2019, 28(6): 533-536.
[19] Portelli, M. and Jones, C.D. (2017) Severe Acute Pancreatitis: Pathogenesis, Diagnosis and Surgical Management. Hepatobiliary & Pancreatic Diseases International: HBPD INT, 16, 155-159. [Google Scholar] [CrossRef] 
[20] 伏添, 栾正刚, 张谞丰. 重症急性胰腺炎并发胰性脑病早期危险因素分析[J]. 东南国防医药, 2021, 23(3): 257-261.
[21] 张永国, 郭晓钟. 胰性脑病的诊治现状[J]. 临床肝胆病杂志, 2017, 33(1): 46-48.
[22] Qiu, F., Lu, X.S. and Huang, Y.K. (2012) Protective Effect of Low-Molecular-Weight Heparin on Pancreatic Encephalopathy in Severe Acute Pancreatic Rats. Inflammation Research: Official Journal of the European Histamine Research Society, 61, 1203-1209. [Google Scholar] [CrossRef] [PubMed]
[23] 程利. 高脂血症性胰腺炎的临床特点分析[J]. 当代医学, 2018, 24(34): 16-18.
[24] 王志毅, 许春芳, 陆婷, 等. 高脂血症性胰腺炎的临床分析[J]. 世界最新医学信息文摘(连续型电子期刊), 2019, 19(16): 40.
[25] 顾春俭. 低分子肝素联合加贝酯治疗高脂血症性胰腺炎疗效观察[J]. 临床医药文献电子杂志, 2017, 4(56): 10939-10940.
[26] 汤娜娜, 王晓燕, 赵成光, 等. 急性高脂血症性胰腺炎患者血清chemerin、降钙素原变化及意义[J]. 中华临床医师杂志(电子版), 2019, 13(1): 31-35.
[27] 戴伟, 周瑞祥, 严骏, 等. 低分子量肝素钙联合胰岛素治疗高脂血症性重症胰腺炎的临床观察[J]. 华中科技大学学报(医学版), 2020, 49(4): 500-503.
[28] Rabenstein, T., Fischer, B., Wiessner, V., et al. (2004) Low-Molecular-Weight Heparin Does Not Prevent Acute Post-ERCP Pancreatitis. Gastrointestinal Endoscopy, 59, 606-613. [Google Scholar] [CrossRef] 
[29] Li, S., Cao, G., Chen, X., et al. (2012) Low-Dose Heparin in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Systematic Review and Meta-Analysis. European Journal of Gastroenterology & Hepatology, 24, 477-481. [Google Scholar] [CrossRef] 

为你推荐